Cycad Group

Prelude is a technology company founded in 2018 and headquartered in Manchester, New Hampshire, that focuses on enhancing cybersecurity defenses for organizations. The company develops products that enable continuous probing of security systems, allowing users to ask critical questions related to their security posture. By translating complex security concepts into actionable inquiries, Prelude provides comprehensive internal intelligence that helps customers identify vulnerabilities and prioritize responses to potential threats. In addition to its technological offerings, Prelude Institute, a subsidiary, is dedicated to addressing the skills gap in the labor market by training individuals for middle-skills careers, particularly in cybersecurity. The institute aims to retrain workers from other industries into security analysts within six months, significantly improving their earning potential and contributing to the workforce's adaptability in a rapidly evolving job landscape.

ImaginAb, Inc. is a clinical stage biotechnology company specializing in immune oncology imaging and radiopharmaceutical therapy. Founded in 2007 and headquartered in Inglewood, California, the company develops targeted imaging agents using its proprietary minibody and cys-diabody platforms. Its lead product, the 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™), is currently in Phase II clinical trials and has been licensed by various pharmaceutical and biotech companies for use in their immunotherapy clinical trials. ImaginAb's portfolio includes precision imaging products for different cancers, such as CD8 and CD4 for immune-oncology, as well as PSMA PET for prostate cancer. By providing actionable insights into patient selection and treatment progress, ImaginAb aims to enhance precision medicine in oncology.

Lixivia, Inc. is a venture-backed start-up based in Santa Barbara, California, founded in 2012. The company specializes in developing innovative processes for the purification and separation of minerals, focusing on cost-effectiveness and scalability. Lixivia addresses critical challenges in re-purposing steel slag by stabilizing it for civil engineering applications and producing high-purity calcium minerals. The company utilizes advanced chemical engineering techniques to refine a variety of mineral mixtures, including low-grade lime, dolime, steel and iron slag, rare earth metals, and lithium. By optimizing these processes, Lixivia enables clients to maximize the value derived from their mineral resources while also reducing emissions associated with mineral extraction.

Formetrix Metals designs patented steel alloys for 3D printed components.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.

ImaginAb, Inc. is a clinical stage biotechnology company specializing in immune oncology imaging and radiopharmaceutical therapy. Founded in 2007 and headquartered in Inglewood, California, the company develops targeted imaging agents using its proprietary minibody and cys-diabody platforms. Its lead product, the 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™), is currently in Phase II clinical trials and has been licensed by various pharmaceutical and biotech companies for use in their immunotherapy clinical trials. ImaginAb's portfolio includes precision imaging products for different cancers, such as CD8 and CD4 for immune-oncology, as well as PSMA PET for prostate cancer. By providing actionable insights into patient selection and treatment progress, ImaginAb aims to enhance precision medicine in oncology.

NanoSteel is an advanced materials company that focuses on the design and commercialization of patented steels with superior mechanical properties derived from their nano-scale microstructure. The company specializes in proprietary alloys, particularly for sheet steel used in automotive lightweight applications. With over 300 patents granted worldwide, NanoSteel has developed innovative ferrous materials, including metallic coatings and additive manufacturing powders. Their nanostructured steel designs are engineered to deliver enhanced performance across various industries, including oil and gas, mining, cement, and power. Recently, NanoSteel introduced advanced high strength steel (AHSS) sheet material, which aims to transform steel utilization in the automotive sector by enabling manufacturers to produce lightweight vehicles that comply with increasing global fuel economy standards while avoiding costly production processes.

Agile RF Systems focuses on the design and development of advanced wireless systems for various applications, including communications, radar, and remote sensing. The company creates small, tactical radars specifically for weather monitoring and counter-unmanned aerial systems (UAS) purposes. Additionally, Agile RF Systems offers satellite communication solutions and develops active electronically steered antennas, as well as millimeter-wave antennas, which facilitate enhanced communication capabilities. By integrating these technologies with multi-channel software-defined radios, the company aims to provide innovative solutions that meet the evolving needs of its clients in the wireless communications sector.

ClarVista Medical, Inc. is a California-based company that specializes in developing innovative products for ophthalmic conditions. Founded in 2012 as a spin-off from a medical device incubator, the company focuses on its flagship product, the HARMONI modular intraocular lens system. This system is designed to optimize vision during cataract surgery by allowing for the initial positioning of the lens and the easy exchange of the lens optic, thus enabling healthcare practitioners to tailor procedures to meet individual patient needs. ClarVista Medical has established a robust portfolio of intellectual property and has conducted clinical studies to validate its technology. The company has secured significant funding to advance the development of the HARMONI system and to pursue necessary regulatory approvals.

SOFIE is a company focused on advancing theranostics through the development of molecular imaging probes and devices. By simplifying the traditionally complex and costly aspects of theranostic technology, SOFIE aims to enhance the adoption and application of its products. The company offers a comprehensive range of imaging and radiochemistry systems, supported by a robust radiopharmacy network and contract manufacturing capabilities. These resources facilitate the supply of novel agents for both diagnosis and therapy, thereby improving patient health outcomes. Furthermore, SOFIE's devices assist physicians in identifying tumors that are responsive to targeted drugs, enabling personalized healthcare solutions and tailored treatment options for patients.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.

ImaginAb, Inc. is a clinical stage biotechnology company specializing in immune oncology imaging and radiopharmaceutical therapy. Founded in 2007 and headquartered in Inglewood, California, the company develops targeted imaging agents using its proprietary minibody and cys-diabody platforms. Its lead product, the 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™), is currently in Phase II clinical trials and has been licensed by various pharmaceutical and biotech companies for use in their immunotherapy clinical trials. ImaginAb's portfolio includes precision imaging products for different cancers, such as CD8 and CD4 for immune-oncology, as well as PSMA PET for prostate cancer. By providing actionable insights into patient selection and treatment progress, ImaginAb aims to enhance precision medicine in oncology.

SOFIE is a company focused on advancing theranostics through the development of molecular imaging probes and devices. By simplifying the traditionally complex and costly aspects of theranostic technology, SOFIE aims to enhance the adoption and application of its products. The company offers a comprehensive range of imaging and radiochemistry systems, supported by a robust radiopharmacy network and contract manufacturing capabilities. These resources facilitate the supply of novel agents for both diagnosis and therapy, thereby improving patient health outcomes. Furthermore, SOFIE's devices assist physicians in identifying tumors that are responsive to targeted drugs, enabling personalized healthcare solutions and tailored treatment options for patients.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

OvaScience, Inc. was a fertility company focused on developing innovative treatments for women facing infertility challenges. The company was founded in 2011 and was headquartered in Waltham, Massachusetts. OvaScience specialized in proprietary technology derived from the discovery of egg precursor (EggPC) cells, which allowed for the enhancement of egg quality and improved outcomes in in vitro fertilization (IVF). Their treatment options included OvaPrime, which aimed to restore a woman's egg production using her own EggPC cells, OvaTure, designed to mature these cells into fertilizable eggs outside the body, and AUGMENT, which utilized mitochondria from EggPC cells to enhance fertilization and pregnancy rates. The company also explored OvaXon for preventing inherited diseases. OvaScience was co-founded by a team of experts from Harvard Medical School and was backed by prominent life science investors. In December 2018, OvaScience was acquired by Millendo Therapeutics in a reverse merger.

ImaginAb, Inc. is a clinical stage biotechnology company specializing in immune oncology imaging and radiopharmaceutical therapy. Founded in 2007 and headquartered in Inglewood, California, the company develops targeted imaging agents using its proprietary minibody and cys-diabody platforms. Its lead product, the 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™), is currently in Phase II clinical trials and has been licensed by various pharmaceutical and biotech companies for use in their immunotherapy clinical trials. ImaginAb's portfolio includes precision imaging products for different cancers, such as CD8 and CD4 for immune-oncology, as well as PSMA PET for prostate cancer. By providing actionable insights into patient selection and treatment progress, ImaginAb aims to enhance precision medicine in oncology.

Iosil Energy Corporation specializes in the production and marketing of high-purity polysilicon, a critical raw material for solar cells. Founded in 2007 and headquartered in Groveport, Ohio, the company has established research and development facilities at the National Institute for Nanotechnology in Edmonton, Alberta. Iosil Energy utilizes innovative technology to purify silicon from waste material generated by wafer sawing operations, known as "kerf." This process not only enhances the purity of the polysilicon produced but also reduces energy consumption and equipment requirements, allowing for a more cost-effective solution for clients in the solar industry.

NanoSteel is an advanced materials company that focuses on the design and commercialization of patented steels with superior mechanical properties derived from their nano-scale microstructure. The company specializes in proprietary alloys, particularly for sheet steel used in automotive lightweight applications. With over 300 patents granted worldwide, NanoSteel has developed innovative ferrous materials, including metallic coatings and additive manufacturing powders. Their nanostructured steel designs are engineered to deliver enhanced performance across various industries, including oil and gas, mining, cement, and power. Recently, NanoSteel introduced advanced high strength steel (AHSS) sheet material, which aims to transform steel utilization in the automotive sector by enabling manufacturers to produce lightweight vehicles that comply with increasing global fuel economy standards while avoiding costly production processes.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

SOFIE is a company focused on advancing theranostics through the development of molecular imaging probes and devices. By simplifying the traditionally complex and costly aspects of theranostic technology, SOFIE aims to enhance the adoption and application of its products. The company offers a comprehensive range of imaging and radiochemistry systems, supported by a robust radiopharmacy network and contract manufacturing capabilities. These resources facilitate the supply of novel agents for both diagnosis and therapy, thereby improving patient health outcomes. Furthermore, SOFIE's devices assist physicians in identifying tumors that are responsive to targeted drugs, enabling personalized healthcare solutions and tailored treatment options for patients.

Solaria Corporation specializes in the design, development, and manufacturing of silicon photovoltaic (PV) products, primarily serving solar system integrators, project developers, and large commercial and utility clients across the United States, Europe, and other international markets. The company offers crystalline solar modules tailored for various mounting systems and installation processes, along with tracking systems that enhance energy capture. In addition to its product offerings, Solaria provides services such as preliminary system design, energy yield optimization, and guidance on balance of system costs. The company also supports its clients with technical specifications, installation assistance, troubleshooting, and after-sales services. Founded in 1993 and originally known as Lightchip, Inc., Solaria Corporation is headquartered in Oakland, California, and has additional operations in Germany, India, and China.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

NanoSteel is an advanced materials company that focuses on the design and commercialization of patented steels with superior mechanical properties derived from their nano-scale microstructure. The company specializes in proprietary alloys, particularly for sheet steel used in automotive lightweight applications. With over 300 patents granted worldwide, NanoSteel has developed innovative ferrous materials, including metallic coatings and additive manufacturing powders. Their nanostructured steel designs are engineered to deliver enhanced performance across various industries, including oil and gas, mining, cement, and power. Recently, NanoSteel introduced advanced high strength steel (AHSS) sheet material, which aims to transform steel utilization in the automotive sector by enabling manufacturers to produce lightweight vehicles that comply with increasing global fuel economy standards while avoiding costly production processes.

Alaunos Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer, specifically through adoptive TCR-T cell therapy. The company utilizes a unique gene expression and control technology to deliver DNA that targets neoantigens derived from genomic mutations in solid tumors. This approach aims to enhance the immune response against cancer cells. Alaunos is currently conducting Phase 2 clinical studies to evaluate the efficacy of its therapies, including the immune system cytokine interleukin-12 for breast cancer and advanced melanoma. Additionally, the company is exploring multiple investigational new drug applications for new therapeutic targets, leveraging its advanced technology to improve treatment outcomes for patients.

[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

PsiloQuest develops and commercializes CMP polishing pads for the semiconductor industry.

Catalytic Solutions manufactures and distributes emissions control systems and catalytic products for commercial and industrial applications. It manufactures nanostructured catalysts at its main facility in Oxnard, California. The company’s products are most commonly applied to automobile, diesel engine, and energy markets. Catalytic Solutions has manufacturing facilities in Oxnard, California; Reno, Nevada; Thornhill, Canada; and Malmo, Sweden. Catalytic Solutions, Inc. operates as a subsidiary of Clean Diesel Technologies Inc.

Catalytic Solutions manufactures and distributes emissions control systems and catalytic products for commercial and industrial applications. It manufactures nanostructured catalysts at its main facility in Oxnard, California. The company’s products are most commonly applied to automobile, diesel engine, and energy markets. Catalytic Solutions has manufacturing facilities in Oxnard, California; Reno, Nevada; Thornhill, Canada; and Malmo, Sweden. Catalytic Solutions, Inc. operates as a subsidiary of Clean Diesel Technologies Inc.